MAY 24, 2018 12:48 AM PDT

The Link Between Tuberculosis and Parkinson Disease

WRITTEN BY: Nouran Amin

There might be a link between Tuberculosis (TB) and Parkinson’s according to a study published in The EMBO Journal. This link is related to the mechanism behind how our immune system eradicates bacterial infections. More specifically, the study concluded that the mechanism is the same for Tuberculosis and Parkinson.

The findings, which will be published in The EMBO Journal, provide a possible explanation of the cause of Parkinson's disease and suggest that drugs designed to treat Parkinson's might work for TB too.

For Parkinson's disease, the most common genetic mutation occurs on the LRRK2, which allows the LRRK2 protein overactive. By examining the function of LRRK2 in immune cells known as macrophages that are infected with Mycobacterium tuberculosis (Mtb), the bacterium that leads to TB.

Using a combination of experimental approaches, Crick and GSK researchers, in collaboration with Matthias Trost, a proteomics specialist, from Newcastle University, discovered that LRRK2 inhibits phagosomes from fusing with lysosomes, decreasing their efficacy at clearing bacteria. Deletion of the LRRK2 gene or cell treatment using LRRK2 blockers might significantly reduce the levels of Mtb, treating TB. "We think that this mechanism might also be at play in Parkinson's disease, where abnormal masses of protein called 'Lewy bodies' build up in neurons in the brain and cause damage," explains Susanne Herbst, the first author of the study and post-doctoral fellow at the Crick.

Investigators suspect that LRRK2 might inhibit immune cells in the brain from degrading causing a build-up of protein in neurons that disrupts their neuronal function. "By studying TB, we have found a possible explanation for why LRRK2 mutations are a genetic risk factor for Parkinson's disease. It's exciting when different fields of research connect up in unexpected ways like this!" notes Susanne.

The findings also suggest that LRRK2 inhibitors could be a powerful new way for TB treatment. "LRRK2 inhibiting drugs are already being developed to treat Parkinson's disease and we're trying to see if we can repurpose them as a potential new TB therapy. This should be relatively straightforward because TB infects the lungs, so the LRRK2 inhibitors wouldn't need to cross the blood-brain barrier like they do in Parkinson's disease."

Sources: Crick

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 30, 2018
Immunology
JUN 30, 2018
CD4 T Cells Responsible for Inflammatory Bowel Disease
A specific subset of immune cells could be targeted to better treat inflammatory bowel disease (IBD). A new University of Alabama at Birmingham study point...
JUL 05, 2018
Health & Medicine
JUL 05, 2018
Is Testing Everyone for Hep C Necessary?
Cases of Hepatitis C, known as Hep C or HCV, are on the rise. In the United States, the CDC reports that there were approximately 3,000 new cases of hepati...
JUL 06, 2018
Cell & Molecular Biology
JUL 06, 2018
Small Molecules Found to Dial Down Autoimmunity
Scientists have now identified two combinations of small molecules that tamp down a protein called STING....
JUL 12, 2018
Videos
JUL 12, 2018
Why Poison Ivy Makes us Itch
For some people, summer comes with a risk of many itchy nuisances, including poison ivy....
AUG 27, 2018
Immunology
AUG 27, 2018
Undiscovered Tunnels from Bone Marrow To Brain
Newly discovered tunnels connect bone marrow of the skull directly to lining of the brain to allow for quick access of immune cells to brain damaged tissues....
OCT 09, 2018
Immunology
OCT 09, 2018
Complement Function Expands
Additional roles to complement protein C3 have been described in work performed by a team of researchers at the Lund University in Sweden...
Loading Comments...